Four years ago, Corbus Pharmaceuticals claimed success in a mid-stage clinical trial of its lead drug, lenabasum, announcing that it improved symptoms in patients with a chronic, connective tissue disease. That rosy view wasn’t universally embraced — some people, myself included, looked at the same data back then and didn’t see much efficacy at all.
Corbus advanced lenabasum into a Phase 3 clinical trial, which was recently completed and the results of which are now being analyzed. The company is expected to announce top-line data before the end of the summer, which will mark a pivotal moment for Corbus.
About the Author Reprints
